NasdaqGM - Delayed Quote • USD
Foghorn Therapeutics Inc. (FHTX)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:20 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 5 | 5 |
| Avg. Estimate | -0.63 | -0.65 | -2.13 | -1.34 |
| Low Estimate | -0.87 | -0.88 | -2.53 | -2.18 |
| High Estimate | -0.51 | -0.53 | -1.8 | -0.55 |
| Year Ago EPS | -0.73 | -0.7 | -2.34 | -2.13 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 4 |
| Avg. Estimate | 6.91M | 6.97M | 29.22M | 34.16M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 12.5M | 12.5M | 50M | 60M |
| Year Ago Sales | 5.04M | -- | 34.16M | 29.22M |
| Sales Growth (year/est) | 37.10% | -- | -14.40% | 16.90% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.72 | -0.73 | -0.75 | -0.76 |
| EPS Actual | -0.73 | -0.7 | -0.34 | -0.57 |
| Difference | -0.01 | 0.03 | 0.41 | 0.19 |
| Surprise % | -1.40% | 4.10% | 54.70% | 25.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.63 | -0.65 | -2.13 | -1.34 |
| 7 Days Ago | -0.63 | -0.65 | -2.13 | -1.34 |
| 30 Days Ago | -0.63 | -0.65 | -2.13 | -1.34 |
| 60 Days Ago | -0.69 | -0.71 | -2.25 | -1.85 |
| 90 Days Ago | -0.69 | -0.71 | -2.25 | -1.86 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | FHTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 13.70% | -- | -- | 6.50% |
| Next Qtr. | 7.10% | -- | -- | 12.00% |
| Current Year | 9.00% | -- | -- | 5.30% |
| Next Year | 37.10% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Wedbush: Outperform to Outperform | 4/10/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/10/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 3/8/2024 |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 11/13/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/7/2023 |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 7/6/2023 |
Related Tickers
STTK Shattuck Labs, Inc.
10.59
+8.28%
LYEL Lyell Immunopharma, Inc.
2.1700
-1.36%
PRLD Prelude Therapeutics Incorporated
4.0700
+0.74%
CGEM Cullinan Therapeutics, Inc.
25.30
+31.43%
ELVN Enliven Therapeutics, Inc.
17.18
+2.38%
ALXO ALX Oncology Holdings Inc.
16.86
-0.06%
BCAB BioAtla, Inc.
2.5400
+12.89%
NBTX Nanobiotix S.A.
5.74
-1.03%
AGIO Agios Pharmaceuticals, Inc.
31.49
-0.57%
PMVP PMV Pharmaceuticals, Inc.
1.7500
+2.34%